Heron Therapeutics (HRTX) Misses Q3 EPS by 9c

Heron Therapeutics (NASDAQ: HRTX) reported Q3 EPS of ($0.10), $0.09 worse than the analyst estimate of ($0.01). Revenue for the quarter came in at $38.2 million versus the consensus estimate of $39.49 million.

For earnings history and earnings-related data on Heron Therapeutics (HRTX) click here.

You May Also Be Interested In

• Anthropic Signs $35b Cloud Deal With Lambda In Texas: WSJ
• Altrova Health Reports Third Quarter Fiscal 2026 Financial Results
• Lobe Sciences Ltd. Announces Closing of Upsize to Non-Brokered Private Placement